Coherus Oncology, Inc.
Financials
Valuation Metrics
Coherus Oncology, Inc.'s Market Cap is $115M. At end of 2025 it was $171M. Ranked #3040 of 3,118 in US market (top 97%), #1404 of 1,474 on NASDAQ (top 95%), #255 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 96%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $115M | US#3,040/3,118 Sec#255/265 |
| Revenue | $51M | US#2,740/3,118 Sec#147/265 |
| Net Income | $-131M | US—/3,118 Sec—/265 |
| Total Assets | $191M | US#2,989/3,118 Sec#246/265 |
| Net Assets | $61M | US#2,837/3,118 Sec#219/265 |
| Employees | 144 | US#2,546/3,118 Sec#149/265 |
| Value | ||
| P/B | 1.90x | US#1,348/3,118 Sec#69/265 |
| P/S | 2.27x | US#1,509/3,118 Sec#41/265 |
| FCF Yield | -161.17% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROA | -68.50% | US#3,021/3,118 Sec#237/265 |
| Op. Margin | -307.43% | US#2,759/3,118 Sec#142/265 |
| Financial Health | ||
| Debt Ratio | 214.25% | US#1,840/3,118 Sec#201/265 |
| Total Debt | $38M | US#2,647/3,118 Sec#166/265 |
| FCF | $-186M | US#2,762/3,118 Sec#202/265 |
| Cash | $83M | US#2,326/3,118 Sec#186/265 |
| Current Ratio | 1.77x | US#1,395/3,118 Sec#228/265 |
| Performance | ||
| 1Y Return | -55.46% | US#2,881/3,118 Sec#237/265 |
| 1M Return | -35.49% | US#3,004/3,118 Sec#253/265 |
| From 52W High | -71.44% | US#2,949/3,118 Sec#234/265 |
| 1Y MDD | -70.19% | US#2,876/3,118 Sec#227/265 |
| Trading | ||
| Volume | 2,525,654 shares | US#901/3,118 Sec#79/265 |
| Trading Value | $2M | US#2,898/3,118 Sec#242/265 |
| Per Share | ||
| EPS | $-0.85 | US—/3,118 Sec—/265 |
| BPS | $0.39 | US#2,754/3,118 Sec#220/265 |
Company Info
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.